Ally Bridge Group (Ny) LLC Janux Therapeutics, Inc. Transaction History
Ally Bridge Group (Ny) LLC
- $76.1 Million
- Q1 2025
A detailed history of Ally Bridge Group (Ny) LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 81,292 shares of JANX stock, worth $1.86 Million. This represents 2.88% of its overall portfolio holdings.
Number of Shares
81,292
Previous 90,292
9.97%
Holding current value
$1.86 Million
Previous $4.83 Million
54.61%
% of portfolio
2.88%
Previous 5.49%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
190Shares Held
57.9MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$255 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$105 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$83.4 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$76 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$53.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $951M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...